Seres Therapeutics (MCRB) Reports Q2 Loss of $0.69/Share

Seres Therapeutics (NASDAQ: MCRB) reported Q2 EPS of ($0.69), versus ($0.70) reported last year. Revenue for the quarter came in at $3.01 million, versus $3 million reported last year.

For earnings history and earnings-related data on Seres Therapeutics (MCRB) click here.

You May Also Be Interested In

• H.C. Wainwright Starts Seres Therapeutics (MCRB) at Buy
• OneMain (OMF) Reiterated at Market Outperform by Citizens on Updated Estimates
• RBC Capital Starts Molina Healthcare (MOH) at Sector Perform